1. "2018"
Formats
  1. Journal Article (3011)
  2. Meeting Abstract (1948)
  3. Book Section (206)
  4. Conference Paper (38)
  5. Book Whole (11)
  6. Editorial (4)
  7. Review (4)
  8. Miscellaneous (2)
  9. Correspondence (1)
Groups
  1. Department of Medicine (2296)
  2. Solid Tumor Oncology Division (1378)
  3. GSK Faculty (1136)
  4. Sloan Kettering Institute Postdocs (1044)
  5. Surgery (870)
  6. Center for Hematologic Malignancies (863)

More Groups

People
  1. Sergio Giralt (87)
  2. Matthew Hellmann (78)
  3. Jedd Wolchok (74)
  4. Marc Ladanyi (74)
  5. Robert Motzer (71)
  6. Nancy Lee (64)

More People

Years
  1. 2018 (5225)
Publications
  1. Journal of Clinical Oncology (562)
  2. Blood (249)
  3. Cancer Research (183)
  4. Annals of Oncology (140)
  5. International Journal of Radiation Oncology, Biology, Physics (137)
  6. Modern Pathology (127)

More Publications

Publishers
  1. Elsevier Inc. (691)
  2. American Society of Clinical Oncology (605)
  3. Springer (410)
  4. American Association for Cancer Research (299)
  5. Oxford University Press (291)
  6. American Society of Hematology (273)

More Publishers

Results (5225)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PD-L1 expression, tumor mutation burden and response to immune checkpoint blockade in patients with HER2-mutant lung cancers
    Meeting Abstract

    Lai, W. C. V.; Feldman, D. L.; Buonocore, D. J.; Brzostowski, E. B.; Rizvi, H.; Plodkowski, A. J.; Ni, A.; Sabari, J. K.; Offin, M. D.; Kris, M. G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Frequency of brain metastases and outcomes in patients with HER2-, KRAS-, and EGFR-mutant lung cancers
    Meeting Abstract

    Kris, M. G.; Offin, M. D.; Feldman, D. L.; Ni, A.; Lai, W. C. V.; Arbour, K. C.; Daras, M.; Pentsova, E.; DeAngelis, L. M.; Beal, K.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600-mutant relapsed refractory low-grade glioma
    Meeting Abstract

    Kieran, M. W.; Bouffet, E.; Broniscer, A.; Cohen, K. J.; Geoerger, B.; Hansford, J. R.; Hingorani, P.; Aerts, I.; Andre, N.; Bertozzi-Salamon, A. I.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Impact of cancer on employment and finances in young adult (YA) survivors
    Meeting Abstract

    Ketterl, T. G.; Casillas, J. N.; Ganz, P. A.; Jacobs, L. A.; McCabe, M. S.; Palmer, S. C.; Partridge, A. H.; Rajotte, E. J.; Risendal, B. C.; Rosenstein, D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC)
    Meeting Abstract

    Kim, D. W.; Gadgeel, S. M.; Gettinger, S. N.; Riely, G. J.; Oxnard, G. R.; Mekhail, T.; Schmid, P.; Dowlati, A.; Heist, R. S.; Wozniak, A. J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Plasma cell-free DNA for noninvasive molecular profiling in high-risk stage 4 neuroblastoma
    Meeting Abstract

    Kothari, P.; Yang, J.; Berger, M. F.; Shukla, N. N.; Modak, S.; Tsui, D.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer
    Meeting Abstract

    Kelly, R. J.; Lee, J.; Bang, Y. J.; Almhanna, K.; Murphy, M. A. B.; Catenacci, D. V. T.; Chung, H. C.; Wainberg, Z. A.; Gibson, M.; Lee, K. W.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Kelley, R. K.; Ryoo, B. Y.; Merle, P.; Park, J. W.; Bolondi, L.; Chan, S. L.; Lim, H. Y.; Baron, A. D.; Parnis, F.; Knox, J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 1 multicenter study evaluating the safety and efficacy of MHC class II-restricted MAGE-A3/A6 T-cell receptor engineered T cells (KITE-718) in patients with advanced cancers
    Meeting Abstract

    Kebriaei, P.; Klebanoff, C. A.; Creelan, B. C.; Hong, D. S.; Blumenschein, G. R.; Drakaki, A.; Tewari, A.; Thomrongsith, L.; Jiang, Y.; Jain, R. K.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic sarcoma
    Meeting Abstract

    Kelly, C. M.; Bowler, T. G.; Munhoz, R. R.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Dholakia, R.; Condy, M. M.; Singer, S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save